VG Life Sciences Obtains 2-Year Funding and Support from MedBridge

VG Life Sciences Inc (OTCPINK:VGLS) announced that it has signed a 2-year financial and administrative support commitment from investor, MedBridge LLC.

As quoted in the press release:

Haig Keledjian, CEO of VG Life Sciences, said, “This is a transformational development for VG Life Sciences. The significant commitment from MedBridge provides us with the capital and operational infrastructure to focus our efforts on advancing our pipeline of preclinical drug candidates into Phase I human clinical trials. Over the next two years, we expect to complete the required preclinical safety, pharmacology, and toxicity studies to move our targeted peptide technologies into Phase I clinical trials for several applications, including HIV, Lyme Disease, and inflammatory syndromes, such as preeclampsia. We anticipate completing the pre-clinical studies within the next six to eight months.

Click here to read the full VG Life Sciences Inc (OTCPINK:VGLS) press release.